IDEAYA Biosciences Inc. (NASDAQ: IDYA) has enrolled its first patient in a Phase 1 clinical trial evaluating IDE892, an inhibitor ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE